138 related articles for article (PubMed ID: 12550076)
1. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.
Svensson J; Boguszewski CL; Shibata F; Carlsson B; Carlsson LM; Bengtsson BA
Growth Horm IGF Res; 2003 Feb; 13(1):1-7. PubMed ID: 12550076
[TBL] [Abstract][Full Text] [Related]
2. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
4. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA
J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705
[TBL] [Abstract][Full Text] [Related]
5. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
Svensson J; Carlsson B; Carlsson LM; Jansson JO; Bengtsson BA
Clin Endocrinol (Oxf); 1999 Apr; 50(4):451-6. PubMed ID: 10468903
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
7. Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery.
Boguszewski CL; Johannsson G; Bengtsson BA; Johansson A; Carlsson B; Carlsson LM
J Clin Endocrinol Metab; 1997 May; 82(5):1516-21. PubMed ID: 9141543
[TBL] [Abstract][Full Text] [Related]
8. Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men.
Hashimoto Y; Kamioka T; Hosaka M; Mabuchi K; Mizuchi A; Shimazaki Y; Tsunoo M; Tanaka T
J Clin Endocrinol Metab; 2000 Feb; 85(2):601-6. PubMed ID: 10690862
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS
Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of 20K-hGH and 22K-hGH isoforms in acromegalic patients.
Lima GAB; Gadelha MR; Strasburger CJ; Wu Z
Front Horm Res; 2010; 38():87-93. PubMed ID: 20616499
[TBL] [Abstract][Full Text] [Related]
11. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
12. Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH.
Tsushima T; Katoh Y; Miyachi Y; Chihara K; Teramoto A; Irie M; Hashimoto Y
J Clin Endocrinol Metab; 1999 Jan; 84(1):317-22. PubMed ID: 9920101
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone isoforms in newborns and postpartum women.
Boguszewski CL; Boguszewski MC; de Zegher F; Carlsson B; Carlsson LM
Eur J Endocrinol; 2000 Apr; 142(4):353-8. PubMed ID: 10754476
[TBL] [Abstract][Full Text] [Related]
15. Twenty-kilodalton human growth hormone (20K hGH) secretion from growth hormone-secreting pituitary adenoma cells in vitro.
Murakami Y; Mori T; Koshimura K; Kurosaki M; Takenobu A; Hashimoto Y; Kato Y
Endocr J; 2000 Oct; 47(5):563-8. PubMed ID: 11200936
[TBL] [Abstract][Full Text] [Related]
16. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
18. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R; Pezzoli SS; Oliveri MC; Patrie JT; Harrell FE; Clasey JL; Heymsfield SB; Bach MA; Vance ML; Thorner MO
Ann Intern Med; 2008 Nov; 149(9):601-11. PubMed ID: 18981485
[TBL] [Abstract][Full Text] [Related]
19. Detection of exogenous growth hormone (GH) administration by monitoring ratio of 20kDa- and 22kDa-GH in serum and urine.
Momomura S; Hashimoto Y; Shimazaki Y; Irie M
Endocr J; 2000 Feb; 47(1):97-101. PubMed ID: 10811299
[TBL] [Abstract][Full Text] [Related]
20. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
